Basilea Pharmaceutica AG logo

BSLN - Basilea Pharmaceutica AG Share Price

CHF51.95 0.7  1.4%

Last Trade - 14/08/20

Mid Cap
Market Cap £465.9m
Enterprise Value £539.2m
Revenue £104.2m
Position in Universe 448th / 1031
Unlock BSLN Revenue
Relative Strength (%)
1m +0.79%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -16.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
42.5 51.7 65.0 90.7 106.1 114.8 133.6 155.3 +22.0%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Basilea Pharmaceutica AG revenues increased 17% to SF62.2M. Net income totaled SF9.9M vs. loss of SF15.4M. Revenues reflect Product revenue increase of 20% to SF30.5M, Contract Revenue increase of 14% to SF31.5M, Revenue Sales of Goods & Services increase of 66% to SF201K. Net Income reflects Research & development expenses, net decrease of 14% to SF43.9M (expense), Selling/General/Admin.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


BSLN Revenue Unlock BSLN Revenue

Net Income

BSLN Net Income Unlock BSLN Revenue

Normalised EPS

BSLN Normalised EPS Unlock BSLN Revenue

PE Ratio Range

BSLN PE Ratio Range Unlock BSLN Revenue

Dividend Yield Range

BSLN Dividend Yield Range Unlock BSLN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BSLN EPS Forecasts Unlock BSLN Revenue
Profile Summary

Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant bacterial infections, systemic fungal infections and drug-resistant tumors. The Company’s anti-infectives, including isavuconazole and ceftobiprole are in late-stage clinical development, while the novel antibiotic, BAL30072 and the oncology compound, BAL101553 are in clinical phase I. The Company’s subsidiaries include Basilea Pharmaceutica China Ltd., Basilea Pharmaceuticals A/S, Basilea Pharma SAS, Basilea Pharmaceutica Deutschland GmbH, Basilea Pharmaceutica International Ltd., BPh Investitionen Ltd., Basilea Medical Ltd. and Basilea Pharmaceuticals Ltd.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated June 10, 2002
Public Since March 25, 2004
No. of Shareholders: n/a
No. of Employees: 225
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange SIX Swiss Exchange
Shares in Issue 10,800,776
Free Float (0.0%)
Eligible for
BSLN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BSLN
Upcoming Events for BSLN
Tuesday 18th August, 2020 Estimate
Half Year 2020 Basilea Pharmaceutica AG Earnings Release
Frequently Asked Questions for Basilea Pharmaceutica AG
What is the Basilea Pharmaceutica AG share price?

As of 14/08/20, shares in Basilea Pharmaceutica AG are trading at CHF51.95, giving the company a market capitalisation of £465.9m. This share price information is delayed by 15 minutes.

How has the Basilea Pharmaceutica AG share price performed this year?

Shares in Basilea Pharmaceutica AG are currently trading at CHF51.95 and the price has moved by 44.86% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Basilea Pharmaceutica AG price has moved by 44.21% over the past year.

What are the analyst and broker recommendations for Basilea Pharmaceutica AG?

Of the analysts with advisory recommendations for Basilea Pharmaceutica AG, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Basilea Pharmaceutica AG is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Basilea Pharmaceutica AG next release its financial results?

Basilea Pharmaceutica AG is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Basilea Pharmaceutica AG dividend yield?

Basilea Pharmaceutica AG does not currently pay a dividend.

Does Basilea Pharmaceutica AG pay a dividend?

Basilea Pharmaceutica AG does not currently pay a dividend.

When does Basilea Pharmaceutica AG next pay dividends?

Basilea Pharmaceutica AG does not currently pay a dividend.

How do I buy Basilea Pharmaceutica AG shares?

To buy shares in Basilea Pharmaceutica AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Basilea Pharmaceutica AG?

Shares in Basilea Pharmaceutica AG are currently trading at CHF51.95, giving the company a market capitalisation of £465.9m.

Where are Basilea Pharmaceutica AG shares listed? Where are Basilea Pharmaceutica AG shares listed?

Here are the trading details for Basilea Pharmaceutica AG:

Country of listing: Switzerland
Exchange: SWX
Ticker Symbol: BSLN
What kind of share is Basilea Pharmaceutica AG?

Based on an overall assessment of its quality, value and momentum, Basilea Pharmaceutica AG is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Basilea Pharmaceutica AG share price forecast 2020?

Shares in Basilea Pharmaceutica AG are currently priced at CHF51.95. At that level they are trading at 69.33% discount to the analyst consensus target price of 0.00.

Analysts covering Basilea Pharmaceutica AG currently have a consensus Earnings Per Share (EPS) forecast of -1.883 for the next financial year.

How can I tell whether the Basilea Pharmaceutica AG share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Basilea Pharmaceutica AG. Over the past six months, the relative strength of its shares against the market has been 0.96%. At the current price of CHF51.95, shares in Basilea Pharmaceutica AG are trading at 5.67% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Basilea Pharmaceutica AG PE Ratio?

We were not able to find PE ratio data for Basilea Pharmaceutica AG.

Who are the key directors of Basilea Pharmaceutica AG?

Basilea Pharmaceutica AG's management team is headed by:

Ronald Scott - DRC
Steven Skolsky - DRC
Laurenz Kellenberger - CSO
Domenico Scala - CHM
Thomas Werner - VCH
David Veitch - CEO
Alf Nicklasson - DRC
Nicole Onetto - DRC
Marc Engelhardt - MGB
Gerrit Hauck - CTO
Anne Stehlin - MGB
Adesh Kaul - CFO
Ursula Eberhardt - OTH
Damian Heller - GCN
Who are the major shareholders of Basilea Pharmaceutica AG?

Here are the top five shareholders of Basilea Pharmaceutica AG based on the size of their shareholding:

Credit Suisse Asset Management Investment Advisor/Hedge Fund
Percentage owned: 5.68% (677k shares)
UBS Asset Management (Switzerland) Investment Advisor
Percentage owned: 5.36% (639k shares)
CI Investments Inc. Investment Advisor/Hedge Fund
Percentage owned: 4.89% (583k shares)
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund
Percentage owned: 3.29% (392k shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 2.73% (325k shares)
Similar to BSLN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.